• 1
    Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychol. Med. 1983; 13: 177183.
  • 2
    Lehman AF, Lieberman JA, Dixon LB et al. Work Group on Schizophrenia. Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd edn. American Psychiatric Association, Washington, DC, 2004.
  • 3
    Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J. Clin. Psychiatry 2001; 62: 153157.
  • 4
    Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005; 353: 12091223.
  • 5
    McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006; 163: 600610.
  • 6
    Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 2006; 163: 611622.
  • 7
    Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 8796.
  • 8
    Coward DM. General pharmacology of clozapine. Br. J. Psychiatry Suppl. 1992; 17: 511.
  • 9
    Beasley CM, Dellva MA, Tamura RN et al. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br. J. Psychiatry 1999; 174: 2330.